Jim Cramer Reports That Eli Lilly and Company (LLY)’s Donanemab Was Approved in Japan For Treating Early Symptomatic Alzheimer’s Disease
Stocks to Watch. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...
precisionmedicineonline1d
Memory Treatment Centers to Study Brain Volume Changes in Alzheimer's Patients on Anti-Amyloid Drugs
The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.
Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom
Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...
McKnight's Long-Term Care News1d
Journalists question safety and effectiveness of new Alzheimer’s drug
A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...
Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab
An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...
i2d
Alzheimer’s ‘wonder drug’ was recommended by scientists funded by pharma firms
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
Daily Express2d
Alzheimer's breakthrough as wonder drug approved - but might not be available in the UK
In the US, the FDA approved a new Alzheimer's treatment in July 2024 called donanemab. The treatment is for people with early symptomatic Alzheimer's disease, including mild cognitive impairment and ...
studyfinds2d
Alzheimer’s drug breakthrough or breakdown? Investigation exposes red flags in FDA approval of donanemab
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
News Medical on MSN2d
Concerns raised over safety and effectiveness of donanemab for Alzheimer’s treatment
The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) ...
BioWorld2d
New Japan drug approvals: cancer, insomnia, Alzheimer’s and more
Japan’s Ministry of Health, Labour and Welfare granted new drug approvals and expanded indications for conditions like cancer, insomnia and Alzheimer’s disease (AD) Sept. 24, including Eli Lilly and ...
BMJ2d
Donanemab: Conflicts of interest found in FDA committee that approved new Alzheimer’s drug
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...
Questions over safety and effectiveness of new Alzheimer's drug
The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...